- Home
- MLYS vs KROS Comparison
MLYS vs KROS Comparison
Compare MLYS & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- KROS
- Stock Information
- Founded
- MLYS 2019
- KROS 2015
- Country
- MLYS United States
- KROS United States
- Employees
- MLYS N/A
- KROS N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- MLYS Health Care
- KROS Health Care
- Exchange
- MLYS Nasdaq
- KROS Nasdaq
- Market Cap
- MLYS 1.0B
- KROS 558.9M
- IPO Year
- MLYS 2023
- KROS 2020
- Fundamental
- Price
- MLYS $14.54
- KROS $13.45
- Analyst Decision
- MLYS Strong Buy
- KROS Buy
- Analyst Count
- MLYS 4
- KROS 13
- Target Price
- MLYS $27.00
- KROS $20.63
- AVG Volume (30 Days)
- MLYS 879.7K
- KROS 603.2K
- Earning Date
- MLYS 08-12-2025
- KROS 08-06-2025
- Dividend Yield
- MLYS N/A
- KROS N/A
- EPS Growth
- MLYS N/A
- KROS N/A
- EPS
- MLYS N/A
- KROS 0.11
- Revenue
- MLYS N/A
- KROS $214,713,000.00
- Revenue This Year
- MLYS N/A
- KROS $5,006.76
- Revenue Next Year
- MLYS N/A
- KROS N/A
- P/E Ratio
- MLYS N/A
- KROS $123.44
- Revenue Growth
- MLYS N/A
- KROS 91657.70
- 52 Week Low
- MLYS $8.24
- KROS $9.12
- 52 Week High
- MLYS $18.38
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- MLYS 50.79
- KROS 43.42
- Support Level
- MLYS $13.22
- KROS $13.24
- Resistance Level
- MLYS $14.35
- KROS $13.77
- Average True Range (ATR)
- MLYS 0.73
- KROS 0.38
- MACD
- MLYS 0.02
- KROS -0.04
- Stochastic Oscillator
- MLYS 81.12
- KROS 28.00
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.